Last reviewed · How we verify
Cefazolin, Bacitracin, Cefalexin
Cefazolin, Bacitracin, Cefalexin is a Beta-lactam antibiotic combination Small molecule drug developed by Population Health Research Institute. It is currently in Phase 3 development for Bacterial infections (specific indication unclear from phase 3 context).
This is a combination of three beta-lactam antibiotics that inhibit bacterial cell wall synthesis by binding to penicillin-binding proteins.
This is a combination of three beta-lactam antibiotics that inhibit bacterial cell wall synthesis by binding to penicillin-binding proteins. Used for Bacterial infections (specific indication unclear from phase 3 context).
At a glance
| Generic name | Cefazolin, Bacitracin, Cefalexin |
|---|---|
| Sponsor | Population Health Research Institute |
| Drug class | Beta-lactam antibiotic combination |
| Target | Penicillin-binding proteins (PBPs); bacterial cell wall |
| Modality | Small molecule |
| Therapeutic area | Infectious Disease |
| Phase | Phase 3 |
Mechanism of action
Cefazolin and cefalexin are cephalosporins that cross-link peptidoglycan in the bacterial cell wall, while bacitracin inhibits cell wall precursor transport. Together, they provide broad-spectrum bactericidal activity against gram-positive and some gram-negative bacteria. This combination approach may enhance coverage or reduce resistance development.
Approved indications
- Bacterial infections (specific indication unclear from phase 3 context)
Common side effects
- Hypersensitivity/allergic reaction
- Gastrointestinal disturbance
- Nephrotoxicity (bacitracin)
Key clinical trials
- Prevention of Arrhythmia Device Infection Trial (PADIT) (PHASE4)
- Prevention of Arrhythmia Device Infection Trial (PADIT) (PHASE4)
- Prevention of Arrhythmia Device Infection Trial (PADIT Pilot) (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Cefazolin, Bacitracin, Cefalexin CI brief — competitive landscape report
- Cefazolin, Bacitracin, Cefalexin updates RSS · CI watch RSS
- Population Health Research Institute portfolio CI
Frequently asked questions about Cefazolin, Bacitracin, Cefalexin
What is Cefazolin, Bacitracin, Cefalexin?
How does Cefazolin, Bacitracin, Cefalexin work?
What is Cefazolin, Bacitracin, Cefalexin used for?
Who makes Cefazolin, Bacitracin, Cefalexin?
What drug class is Cefazolin, Bacitracin, Cefalexin in?
What development phase is Cefazolin, Bacitracin, Cefalexin in?
What are the side effects of Cefazolin, Bacitracin, Cefalexin?
What does Cefazolin, Bacitracin, Cefalexin target?
Related
- Drug class: All Beta-lactam antibiotic combination drugs
- Target: All drugs targeting Penicillin-binding proteins (PBPs); bacterial cell wall
- Manufacturer: Population Health Research Institute — full pipeline
- Therapeutic area: All drugs in Infectious Disease
- Indication: Drugs for Bacterial infections (specific indication unclear from phase 3 context)
- Compare: Cefazolin, Bacitracin, Cefalexin vs similar drugs
- Pricing: Cefazolin, Bacitracin, Cefalexin cost, discount & access